Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial

Abstract Objective This study aimed to assess the efficacy of concurrent magnesium-sodium valproate therapy and compare it with either magnesium or sodium alone in migraine prophylaxis. Materials methods randomized single-center double-blind parallel-group controlled clinical trial was conducted on patients within age range 18–65 years. The subjects at least four monthly attacks were randomly assigned group A ( n = 82) valproate, B 70) C magnesium. passed a one-month baseline without prophylactic then received 3-month treatment. characteristics migraine, including frequency, severity, duration attacks, number painkillers taken per month, recorded each visit. Migraine Disability Assessment (MIDAS) Headache Impact Test-6 (HIT-6) scores after 3 months treatment group. Within- between-group analyses performed this study. Results obtained results revealed significant reduction all groups compared those reported for P < 0.001). Intragroup data analysis indicated that there no statistically difference headache frequency between third month 0.525); nevertheless, three other parameters showed B, 0.05). On hand, could not effectively reduce measured patients, Furthermore, MIDAS HIT-6 significantly diminished A, 0.001), these changes more than Conclusion enhance antimigraine properties combination required dose